Friday, May 28, 2021
Olympus Corporation (”Olympus” –Director,Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition ofIsraeli medical device company Medi-Tate Ltd. (“Medi-Tate”–CEO: Ido Kilemnik)following the announcement of itsdecision to exercise the call option in February, 2021. Through this acquisition, Olympus expands its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidifies its position as a leader in the field of urological devices.
Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment ofBPH. The company’s flagship product “iTind” has receivedU.S. FDA de Novo authorization and a European CE mark. With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.
The incidence of BPH, one of the most common diseases in aging men and the most common cause of lower urinary tract symptoms (“LUTS”), is expected to increase as the general global population gets older. According to the American Urological Association, BPH is a condition that nearly 80% ofmen will face in their lifetime and that ratio is higher in older ages.iMedication and surgical treatment have been among the usual treatment options for BPH, and in recent years, more minimally invasive surgical treatment devices have come to the market.
Olympus is a market leader providing devices for BPH treatment such as resectoscopes and a wide variety of electrodes. By adding the non-ablative BPH treatment device iTind, which allows patients to maintain their sexual function, to its portfolio, Olympus can provide urologists more treatment options according to the symptoms and needs of their patients, ranging from in-offices day treatment to surgical therapies in hospitals.
Nacho Abia, Chief Operating Officerof Olympus Corporation,said,“the acquisition of Medi-Tate aligns with our corporate strategy of focusing on three priority therapeutic areas within our Therapeutic Solutions Division —gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices. Medi-Tate’s innovative products offer a truly minimally invasive treatment option for patients and flexibility in the delivery of care for healthcare professionals.”
Ido Kilemnik, Chief Executive Officer of Medi-Tate, commented, “We believe Olympus appreciatesour focus on long-term clinical results and dedication of the entire Medi-Tate team. Weare pleased to be joining Olympus, which shares our vision of making iTind the global standard for BPH treatment.We are excited to be collaborating with Olympus in our effort to enhance the patients’ quality of life.”
Minimally invasive treatment enabled by iTind
iTind, a temporarily implanted nitinol device, supports thereliefof lower urinary tract symptoms(LUTS)due to BPH.The iTind treatmentisperformed by anurologist in an outpatienthospital, ambulatory surgery centeror in a physician’s office,where the iTind deviceis placedin the prostatein a folded configuration. The deviceslowly expands and exerts gentle pressure at three precise points to reshapetheprostatic urethra and bladder neck.After five to seven days, the device is completely removed, leavingawideropening through which urine can flowfor the relief of BPH symptoms.
i American Urological Association, Benign Prostatic Hyperplasia. Available at: https://www.auanet.org/education/auauniversity/medical-student-education/medical-student-curriculum/bph
Medi-Tate is an Israeli medical device companydedicated to improvingmen’s healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). The flagship iTind treatment for BPH currently has the EU CE Mark and is approved for sale in the European Union, UK, Israel, Australia, Brazil, and the FDA cleared for use in the United States.For more information, visit www.medi-tate.com.
About Olympus’ Therapeutic Solutions business
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Starting with its early contributions to the development of the polypectomy snare, Olympus’ Therapeutic Solutions portfolio has grown to includean array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.